Carol Suh is a Partner with ARCH Venture Partners. She joined the company in 2018 as an Associate and was named Partner in 2021. Carol focuses on identifying and evaluating new life science technologies and is involved in company creation. Carol is a stem cell biologist by training and combines her scientific expertise with experiences on the business side of biotech. Carol is a co-founder and SVP, Strategy at Neumora Therapeutics and helped build Sana Biotechnology, Autobahn Therapeutics and Boundless Bio. Prior to ARCH, Carol helped launch Magenta Therapeutics, a biotech company transforming the way bone marrow stem cell transplants are performed. Previously, she was a consultant at Trinity Partners, working with a wide range of biotech and pharma companies on corporate strategy, market research, and business development. Carol began her career in R&D Strategy with GlaxoSmithKline’s Regenerative Medicine group. For her work, she was recognized on the 2015 Forbes 30 Under 30 list in Healthcare.
Ms. Suh holds an A.B. in Molecular Cellular Biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute. She also holds a M.Phil from Yale University and was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology. She completed her M.B.A. from Stanford Graduate School of Business.